{"id":390388,"date":"2019-06-28T00:00:00","date_gmt":"2019-06-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0001-2019-biopharma-rheumatoid-arthritis-china-in-depth-china-2019\/"},"modified":"2026-04-14T10:25:37","modified_gmt":"2026-04-14T10:25:37","slug":"concim0001-2019-biopharma-rheumatoid-arthritis-china-in-depth-china-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0001-2019-biopharma-rheumatoid-arthritis-china-in-depth-china-2019\/","title":{"rendered":"Rheumatoid Arthritis | China In-Depth | China | 2019"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has globally the highest number of RA patients, and the Chinese RA market boasts six biologics: the TNF-\u03b1 inhibitors etanercept (Amgen\u2019s Enbrel, biosimilars), adalimumab (AbbVie\u2019s Humira), infliximab (Janssen\u2019s Remicade), and golimumab (Janssen\u2019s Simponi); theIL-6 inhibitor tocilizumab (Roche\u2019s Actemra); the B-cell modulator\u00a0rituximab (Roche\u2019s MabThera, biosimilars); and the oral JAK inhibitor\u00a0Xeljanz (tofacitinib). The TNF-\u03b1 inhibitors are the most widely prescribed targeted therapies for RA patients refractory to conventional DMARDs, and other biologics and the JAK inhibitor tofacitinib largely compete for use in TNF-\u03b1-inhibitor-refractory patients. With the expected launch of additional targeted therapies, in addition to the availability of the cost-effective biosimilars of marketed TNF-\u03b1 inhibitors during the forecast period, the Chinese RA market will witness fierce competition and increasing challenges to gain market uptake.<\/p>\n<ul>\n<li>How large is China\u2019s drug-treatable RA population and how will the drug-treatment rate change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s RA market and why? What are interviewed experts\u2019 insights on current treatment options? Which clinical needs remain unfulfilled?<\/li>\n<li>What are the key market access considerations of key therapies in the RA pipeline in China? What sales\/uptake could they secure in RA? What are interviewed experts\u2019 opinion on the key emerging therapies?<\/li>\n<li>What are the key drivers and constraints in the China RA market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access &#038; reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Release date<\/strong><\/p>\n<p>June 2019<\/p>\n<p><strong>Geographies<\/strong><\/p>\n<p>China<\/p>\n<p><strong>Primary Research <\/strong><\/p>\n<p>Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading rheumatologists, supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>Epidemiology<\/strong><\/p>\n<p>Diagnosed prevalence of RA by disease stage. Clinically and market relevant drug-treatable populations.<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient shares of key RA therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions<\/p>\n<p><strong>EMERGING THERAPIES <\/strong><\/p>\n<p>Phase III\/PR: 8 drugs; Phase II: 2 drugs; Coverage of select early-phase products.<\/p>\n","protected":false},"template":"","class_list":["post-390388","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390388\/revisions"}],"predecessor-version":[{"id":576625,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390388\/revisions\/576625"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}